1. Home
  2. SCYX vs VRAR Comparison

SCYX vs VRAR Comparison

Compare SCYX & VRAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.63

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Logo The Glimpse Group Inc.

VRAR

The Glimpse Group Inc.

HOLD

Current Price

$0.97

Market Cap

21.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
VRAR
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
26.5M
21.9M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SCYX
VRAR
Price
$0.63
$0.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$2.62
AVG Volume (30 Days)
458.0K
107.4K
Earning Date
11-05-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,932,000.00
$9,488,209.00
Revenue This Year
$167.73
N/A
Revenue Next Year
$290.78
$72.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.60
52 Week Low
$0.57
$0.89
52 Week High
$1.49
$7.00

Technical Indicators

Market Signals
Indicator
SCYX
VRAR
Relative Strength Index (RSI) 38.09 38.36
Support Level $0.63 $0.89
Resistance Level $0.65 $1.10
Average True Range (ATR) 0.02 0.09
MACD -0.00 0.00
Stochastic Oscillator 5.74 27.59

Price Performance

Historical Comparison
SCYX
VRAR

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About VRAR The Glimpse Group Inc.

The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.

Share on Social Networks: